Brief: Celltrion’S Monoclonal Antibody Treatment Regdanvimab, Approved By European Commission For Treatment Of Covid-19
Nov 14 (Reuters) - Celltrion HealthCare Co Ltd 091990.KQ :
* CELLTRION’S MONOCLONAL ANTIBODY TREATMENT REGDANVIMAB,
APPROVED
BY THE EUROPEAN COMMISSION FOR THE TREATMENT OF COVID-19
* CELLTRION HEALTHCARE - EC GRANTED MARKETING AUTHORISATION
FOR
CO'S REGDANVIMAB AFTER POSITIVE OPINION BY EMA'S CHMP LAST WEEK
* CELLTRION - EC GRANTED MARKETING AUTHORISATION FOR ADULTS
WITH
COVID-19 WHO DO NOT REQUIRE SUPPLEMENTAL OXYGEN & ARE AT RISK OF
SEVERE COVID-19
* CELLTRION HEALTHCARE -CONTINUES TO DISCUSS SUPPLY
AGREEMENTS
WITH REGULATORY AGENCIES, CONTRACTORS IN MORE THAN 30 COUNTRIES
IN EUROPE, ASIA, LATAM
Source text for Eikon: ID:nBw9PTYYJa
Further company coverage: 091990.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Celltrion Healthcare Co
See all newsBrief: Celltrion USA says Ventegra Will Place FDA-Approved Biosimilar To Avastin , Vegzelma On Its Commercial Formulary As A Preferred Brand
Brief: Celltrion Healthcare To Acquire 92.7 Billion Won Worth Of Own Shares
Brief: Celltrion Healthcare Q3 Operating Profit 50.5 Billion Won, Down 30.4% From Year Earlier
Brief: Celltrion Usa- Announces Distribution And Incorporation Of Yuflyma (Adalimumab-Aaty) To Carepartners Specialty Pharmacy Cost Savings Programs
Brief: Celltrion Healthcare's Merger With Celltrion Approved In Shareholder Meeting -Yonhap